Hailshadow Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved cell therapy Carvykti, developed with Legend Biotech (LEGN), outperformed standard of care in a Phase 3 trial for patients with a type of blood cancer called multiple myeloma. Citing interim data from its CARTITUDE-4 trial, the pharma giant said patientsContinue Reading
seb_ra A group of plaintiffs, who allege that Johnson & Johnson’s (NYSE:JNJ) talc-based baby powder caused their cancers, has lost their bid to block the company’s latest effort to use bankruptcy to resolve similar claims after a federal judge rejected their motion. U.S. District Judge Michael Shipp delivered the rulingContinue Reading
Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) has discontinued a Phase 2 trial for its blockbuster arthritis therapy Tremfya in patients with an autoimmune disorder called giant cell arteritis after the study failed to meet the primary goal, according to updated data from a federal register ofContinue Reading
